Skip to main content

Table 1 Demographic and clinical characteristics of patients after first recurrence

From: Recurrent colorectal liver metastasis patients could benefit from repeat hepatic resection

Variable

Local treatment

Systemic chemotherapy

P value

Resection

RFA

Patients demographics

n = 88

n = 85

n = 127

 

Age (years)

55.6 ± 10.3

57.7 ± 9.3

56.1 ± 9.8

0.75

Sex ration (M:F)

57:31

59:26

80:47

0.83

Primary T

 T1-2

7 (8.0%)

7 (8.2%)

18 (14.2%)

0.23

 T3-4

81 (92.0%)

78 (91.8%)

109 (85.8%)

 

Primary N

 N0

54 (61.4%)

66 (77.6%)

94 (74.0%)

0.82

 N1-2

34 (38.6%)

19 (22.4%)

33 (26.0%)

 

Primary tumor location

 Colon

55 (62.5%)

52 (61.2%)

78 (31.4%)

0.95

 Rectum

33 (37.5%)

33 (38.8%)

49 (38.6%)

 

 Right side

24 (27.3%)

17 (20.0%)

34 (26.8%)

0.75

 Left side

64 (72.7%)

68 (80.0%)

93 (73.2%)

 

Timing of liver metastasis

 Synchronous

72 (81.8%)

78 (91.8%)

110 (86.6%)

0.53

 Metachronous

16 (18.2%)

7 (8.2%)

17 (13.4%)

 

 Metastasis no

1 (1–7)

1 (1–3)

2 (1–5)

0.00

 Metastasis size(mm)

23.1 ± 15.8

15.6 ± 1.7

19.6 ± 10.2

0.00

Localization of liver metastases

 Unilobar

63 (71.6%)

70 (82.4%)

72 (56.7%)

0.00

 Bilobar

25 (28.4%)

15 (17.6%)

55 (43.3%)

 

 CEA > 50

13 (14.8%)

4 (4.7%)

5 (3.9%)

0.00

 CA199 > 100

10 (11.4%)

6 (7.1%)

8 (6.3%)

0.18

Ras status

 Wild

62 (70.5%)

50 (58.8%)

77 (60.6%)

0.49

 Mutation

26 (29.5%)

35 (41.2%)

50 (39.4%)

 

 Preoperative chemotherapy

49 (55.7%)

25 (29.4%)

127 (100%)

NA

 Up-front local treatment

39 (44.3%)

60 (70.6%)

0

 

No. of lines

 First line

25 (28.4%)

12 (14.1%)

70 (55.1%)

NA

 Second line

24 (27.3%)

13 (15.3%)

47 (37.0%)

 

 Others

0

0

10 (7.9%)

 

Regimen

 Oxaliplatin

18 (20.5%)

9 (10.6%)

49 (38.6%)

NA

 Irinotecan

31 (35.2%)

16 (18.8%)

70 (55.1%)

 

 Others

0

0

8 (6.3%)

 

 Biological agents

39 (44.3%)

20 (23.5%)

95 (74.8%)

NA

 Bevacizumab

29 (33.0%)

18 (21.2%)

70 (55.1%)

 

 Cetuximab

10 (11.3%)

2 (2.3%)

25 (19.7%)

 

Response to chemotherapy

 Complete

0

0

0

NA

 Partial

4 (4.5%)

2 (2.4%)

21 (16.5%)

 

 Stable disease

45 (51.1%)

23 (27.1%)

89 (70.1%)

 

 Progressive disease

0

0

17 (13.4%)

 

 Intraoperative RFA

8 (9.1%)

NA

NA

 

 Operation time

204.4 ± 89.0

NA

NA

NA

 Blood lose

274.1 ± 77.1

NA

NA

NA

 RBC transfusion

2

NA

NA

NA

 R1 resection

6

NA

NA

NA

 Complication

4

NA

NA

NA

 Major

1

0

NA

NA

 Adjuvant chemotherapy

66 (75%)

62 (73.0%)

NA

NA